A Study to Assess the Clinical Validity of Konectom™ in Adults Living With Neuromuscular Disorders
study id #: NCT05109637
condition: Spinal Muscular Atrophy, Amyotrophic Lateral Sclerosis
status: Not yet recruiting
purpose:The primary objective of the study is to explore the convergent validity of smartphone-based Konectom DOAs against in-clinic standard assessments.
The secondary objectives of this study are to evaluate the test-retest reliability of smartphone-based Konectom Digital Outcome Assessments (DOAs); to determine the relationship between Konectom upper limb DOAs and conventional upper limb assessments in clinical environments; to determine the relationship between Konectom lower limb DOAs and status of ambulation in clinical environments; to evaluate group differences in smartphone-based Konectom DOAs [self-administered at home and in-clinic] between person with spinal muscular atrophy (PwSMA) or person with amyotrophic lateral sclerosis (PwALS) and healthy subjects (HS); to evaluate the variability of Konectom DOAs self-administered in everyday environment in HS and PwSMA or PwALS; to compare Konectom DOAs between in-clinic supervised administration versus self-assessments in everyday environment in HS, PwSMA and PwALS groups; to evaluate the relationship of Konectom DOAs against patient-reported outcomes (PROs) in PwSMA or PwALS and to evaluate the clinical safety of Konectom in PwSMA and PwALS.
intervention: Konectom NMD Application
results: https://clinicaltrials.gov/ct2/show/results/NCT05109637
last updated: February 04, 2022
-
An Infant With Congenital Respiratory Insufficiency and Diaphragmatic Paralysis: A Novel BICD2 Phenotype?Monoallelic pathogenic variants in BICD2...
-
Spinal Muscular Atrophy: From Rags to RichesThe aim of this paper is to provide a sh...
-
Alex Fay, PhDDr. Alex Fay is a pediatric neurologist ...
-
Scholar Rock Provides Corporate Update and Highlights Priorities for 2022Scholar Rock, a clinical-stage biopharma...
-
Lee Rubin, PhDLee Rubin investigates the key molecular...
-
Nonrespiratory Complications of Nusinersen-Treated Spinal Muscular Atrophy Type 1 PatientsBackground: Emergence of new treatments ...
-
Baby Among the First to Receive Gene Therapy for Spinal Muscular Atrophy After FDA Approvalhttps://www.youtube.com/watch?v=adc6vztu...